AU6613100A - Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof - Google Patents

Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof

Info

Publication number
AU6613100A
AU6613100A AU66131/00A AU6613100A AU6613100A AU 6613100 A AU6613100 A AU 6613100A AU 66131/00 A AU66131/00 A AU 66131/00A AU 6613100 A AU6613100 A AU 6613100A AU 6613100 A AU6613100 A AU 6613100A
Authority
AU
Australia
Prior art keywords
stanniocalcin
complications
diabetes
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66131/00A
Inventor
Emma E Moore
Hong Ping Ren
Gary Rosenberg
Angela Thostrud
David S Weigle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Zymogenetics Inc
Original Assignee
University of Washington
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Zymogenetics Inc filed Critical University of Washington
Publication of AU6613100A publication Critical patent/AU6613100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
AU66131/00A 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof Abandoned AU6613100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14659999P 1999-07-30 1999-07-30
US60146599 1999-07-30
PCT/US2000/020668 WO2001008697A2 (en) 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof

Publications (1)

Publication Number Publication Date
AU6613100A true AU6613100A (en) 2001-02-19

Family

ID=22518123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66131/00A Abandoned AU6613100A (en) 1999-07-30 2000-07-28 Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof

Country Status (2)

Country Link
AU (1) AU6613100A (en)
WO (1) WO2001008697A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255825A4 (en) * 2008-01-25 2011-09-14 Regeron Inc Composition for preventing or treating brain diseases
GB0802009D0 (en) * 2008-02-04 2008-03-12 Chroma Therapeutics Ltd Biomarkers of aminopeptidase inhibition
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
US20180236035A1 (en) * 2010-05-03 2018-08-23 Scott & White Healthcare Protein therapy for treatment of retinal diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670377A (en) * 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes

Also Published As

Publication number Publication date
WO2001008697A3 (en) 2001-06-14
WO2001008697A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU3725997A (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
HK1105580A1 (en) Use of isoflavone compounds in the manufacture of medicament and composition comprising the same
IL150260A0 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
AU7319994A (en) Nucleotide preparation and uses thereof in wound healing
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU5240700A (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU3116599A (en) Di-behenyl fumarate and its use in dermatological products
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
AU2418499A (en) Org-5222 in the treatment of depression
AU2121200A (en) Improvements in or relating to sphygmomanometers and other devices
AU6613100A (en) Use of stanniocalcin 2 in the treatment of type ii diabetes and complications thereof
AU7263300A (en) Opaminergic neuronal survival-promoting factors and uses thereof
AU4073299A (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU1031397A (en) Human peptide circulating in the blood and possessing insulinotropic properties
EP1126856A4 (en) Compounds and their therapeutic use with diabetic complications

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase